focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCambridge Cog Share News (COG)

Share Price Information for Cambridge Cog (COG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 45.00
Bid: 44.00
Ask: 46.00
Change: 0.50 (1.12%)
Spread: 2.00 (4.545%)
Open: 44.50
High: 45.00
Low: 44.50
Prev. Close: 44.50
COG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Cambridge Cognition revenue climbs despite swing to annual loss

Wed, 03rd May 2023 17:21

(Alliance News) - Cambridge Cognition Holdings PLC on Wednesday said it had a "transformative" 2022, as revenue climbed 25% against the previous year.

The Cambridge, England-based digital health products technology developer said revenue in 2022 rose to GBP12.6 million, up 25% from GBP10.1 million a year earlier. Services revenue grew by 16% in 2022 to GBP6.5 million, whilst Software revenue climbed 39% to GBP5.0 million.

However, the company swung to a pretax loss of GBP600,000 from a pretax profit of GBP300,000 year-on-year. It also swung to a loss per share of 1.3 pence, from an earnings per share of 1.4 pence.

The financial results for the year were tempered by a slightly slower-than-expected final quarter, as the company experienced delays and scope reduction associated with large orders, Cambridge Cognition explained. It added that market forecasts suggest that this is not representative of a long-term trend.

The company ended 2022 with a contracted order book of GBP17.6 million, which increased further to GBP19.1 million in January, following the acquisition of Winterlight Labs.

Cambridge Cognition bought Winterlight Labs for GBP7.0 million back in January.

Looking ahead, Cambridge Cognition said that its strong contracted order book provides "excellent" revenue visibility through 2023.

"2022 was a transformational year for Cambridge Cognition, marked by significant multi-year orders, sustained revenue growth, and the expansion of our core product set," said Chief Executive Officer Matthew Stork.

"Looking ahead, we remain committed to our objectives of driving revenue and profit growth by increasing our market share through offering the most innovative technology, supported by outstanding scientific evidence and a very experienced team, in the high-value market for CNS drug development."

Shares in Cambridge Cognition closed down 4.6% to 93.00 pence each.

By Sophie Rose, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
9 Jul 2021 11:01

Cambridge Cognition wins GBP1 million contract for cancer trial tests

Cambridge Cognition wins GBP1 million contract for cancer trial tests

Read more
9 Jul 2021 10:52

AIM WINNERS & LOSERS: Evgen disappointed as SFX-01 flops study hurdle

AIM WINNERS & LOSERS: Evgen disappointed as SFX-01 flops study hurdle

Read more
9 Jul 2021 08:33

Cambridge Cognition wins £1.0m contract with 'top ten' pharma company

(Sharecast News) - Software developer Cambridge Cognition has won a £1.0m contract as the cognitive assessment partner for a late phase cancer trial.

Read more
1 Jul 2021 19:26

TRADING UPDATES: Gym Group bulks up with placing; 88 Energy debt free

TRADING UPDATES: Gym Group bulks up with placing; 88 Energy debt free

Read more
1 Jul 2021 11:31

AIM WINNERS & LOSERS: Biome Technologies plunges after profit warning

AIM WINNERS & LOSERS: Biome Technologies plunges after profit warning

Read more
28 Jun 2021 12:04

IN BRIEF: Cambridge Cognition nets GBP2.2 million contract

IN BRIEF: Cambridge Cognition nets GBP2.2 million contract

Read more
28 Jun 2021 11:17

Cambridge Cognition selected as cognitive assessment partner for large at-home study

(Sharecast News) - Cognitive assessment software provider Cambridge Cognition has been selected as the cognitive assessment partner for a large at-home study, its second such award in the last two months.

Read more
28 Jun 2021 11:16

AIM WINNERS & LOSERS: Croma Security rises on raised guidance

AIM WINNERS & LOSERS: Croma Security rises on raised guidance

Read more
14 Jun 2021 14:36

IN BRIEF: Cambridge Cognition wins GBP1.4 million in medical contracts

IN BRIEF: Cambridge Cognition wins GBP1.4 million in medical contracts

Read more
11 Jun 2021 19:50

TRADING UPDATES: Zephyr eyes US investors; Good Energy's Zap-Map boost

TRADING UPDATES: Zephyr eyes US investors; Good Energy's Zap-Map boost

Read more
2 Jun 2021 16:23

Cambridge Cognition elevates Mick Holton to executive board

(Sharecast News) - Brain health technology company Cambridge Cognition announced on Wednesday that Michael 'Mick' Holton would join the board as an executive director, with immediate effect.

Read more
2 Jun 2021 16:02

EXECUTIVE CHANGES: CEO departs after GLI Finance becomes Sancus

EXECUTIVE CHANGES: CEO departs after GLI Finance becomes Sancus

Read more
20 May 2021 16:07

UK shareholder meetings calendar - next 7 days

UK shareholder meetings calendar - next 7 days

Read more
8 Apr 2021 12:48

Cambridge Cognition wins at-home clinical trial contract

(Sharecast News) - Brain health technology company Cambridge Cognition has won a contract with a new pharmaceutical client to provide cognitive assessments in an at-home clinical trial, it announced on Thursday.

Read more
8 Apr 2021 11:56

Cambridge Cognition shares up 21% after new GBP500,000 contract win

Cambridge Cognition shares up 21% after new GBP500,000 contract win

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.